In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against Pseudomonas aeruginosa isolated from patients with cystic fibrosis

Patrick J. Nolan, Raksha Jain, Leah Cohen, James D. Finklea, Tiffeny T. Smith

Research output: Contribution to journalArticlepeer-review

Abstract

Pseudomonas aeruginosa is a commonly isolated pathogen in adults with cystic fibrosis (CF). Antimicrobial resistance is an escalating problem due to chronic colonization and frequent antimicrobial exposure. Ceftolozane-tazobactam (C/T) and ceftazidime-avibactam (CZA) exhibit promising activity against antimicrobial resistant organisms, including P. aeruginosa. A retrospective review was conducted comparing the in vitro activities of C/T and CZA against 42 P. aeruginosa isolates from the respiratory tract of 32 adults with CF. The first isolate per patient per year that underwent susceptibility testing for C/T, CZA, and colistin was included. C/T was more susceptible than CZA (60% versus 43%). Thirty-eight (90%) isolates were considered highly drug resistant and demonstrated higher C/T susceptibilities compared to CZA (55% versus 45%). These results suggest using C/T while awaiting susceptibilities when standard antipseudomonal agents cannot be used.

Original languageEnglish (US)
Article number115204
JournalDiagnostic Microbiology and Infectious Disease
Volume99
Issue number2
DOIs
StatePublished - Feb 2021

Keywords

  • Ceftazidime-avibactam
  • Ceftolozane-tazobactam
  • Cystic fibrosis
  • Pseudomonas
  • Respiratory tract

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against Pseudomonas aeruginosa isolated from patients with cystic fibrosis'. Together they form a unique fingerprint.

Cite this